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2013, accepted Aptherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in developed and developing countries.
Despite decades of effort, unhealthy lifestyle habits and ASCVD risk factor levels remain high and are increasing
in many population groups. A new approach to ASCVD prevention is needed. Multiple lines of evidence from animal
and human studies suggest that atherosclerosis regression and normalization of vessel function can occur when
low-density lipoprotein cholesterol (LDL-C) lowering occurs early in the course of atherosclerosis or when very
aggressive LDL-C lowering occurs somewhat later. We propose a new paradigm focused on curing atherosclerosis
early in the course of the disease. An approach that resets the vascular aging clock composed of initial regression
therapy followed by periodic retreatment to suppress atherosclerosis development may be possible, with the
ultimate goal of preventing subsequent ASCVD events. Proof-of-concept studies are needed to determine: 1) the
optimal age and/or extent of atherosclerosis for intervention and LDL-C–lowering therapy; 2) the intensity and
duration of therapy for inducing atherosclerosis regression; and 3) documenting the normalization of vascular
function. Ultimately, this new paradigm will need to be evaluated in ASCVD outcomes trials. (J Am Coll Cardiol
2014;63:2779–85) ª 2014 by the American College of Cardiology FoundationDespite dramatic declines, atherosclerotic cardiovascular
disease (ASCVD) remains the leading cause of death in
developed countries (1). High levels of unhealthy behaviors
and ASCVD risk factors remain prevalent in adults (2).
Secular trends in improved levels of low-density lipoprotein
cholesterol (LDL-C), blood pressure, and tobacco use have
been offset by increasing rates of obesity and type 2 diabetes
mellitus (3). Children, adolescents, and young adults have
an increasing burden of cardiovascular risk due to the
increasing rate of obesity over the past 30 years, associated
with higher rates of type 2 diabetes, increasing blood pres-
sure, and dyslipidemia (4).See page 2786Clearly, continued population-based efforts to improve
lifestyle and control risk factors are needed. However, given
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ril 14, 2014.adults, the worsening ASCVD risk factors in children and
the magnitude of behavioral and societal changes needed to
achieve optimal cardiovascular health, new approaches to
ASCVD prevention will also be needed to combat the global
epidemic of ASCVD. In this paper, we provide the rationale
for a new paradigm for resetting the vascular aging clock,
consisting of a short-term, aggressive LDL-C–lowering
intervention early in the course of atherosclerosis to induce
atherosclerotic regression and normalize vascular function,
in essence “curing” atherosclerosis. If proven in ASCVD
outcomes trials, widespread uptake of a strategy of regression
treatment early in adolescence and early adulthood, with
re-treatment periodically through adulthood, could ulti-
mately eliminate ASCVD as a signiﬁcant cause of morbidity
and mortality.
Atherosclerosis begins early. Atherosclerosis begins at a
very young age with the development of low-grade lesions
(5,6). The earliest lesions of atherosclerosis are present in
late adolescence (5,6). Advanced lesions develop in the third
and early fourth decades of life, particularly in men with
established cardiovascular risk factors. Multiple longitudinal
studies have shown that risk factors present in adolescence
and young adulthood are stronger determinants of subclin-
ical atherosclerosis 15 to 20 years later than risk factors
measured at the time of the subclinical imaging study (7).
Important among these are higher levels of LDL-C and
non–high-density lipoprotein cholesterol (HDL-C), as
evidenced by the early development of atherosclerosis in
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2780younger persons with lower levels
of LDL-C and non–HDL-C
may still have a high risk of early
atherosclerosis due to the pres-
ence of other ASCVD risk fac-
tors (9). Diabetes in youth is also
associated with advanced athero-
sclerosis in adolescence. Further
analysis of these cohorts has
shown that individuals whose risk
factors improve over the 15- to
20-year interval between risk
assessment and subclinical ath-
erosclerosis measurement have a
much lower likelihood of later
subclinical disease (10).
A new approach to preventing/
curing atherosclerosis. The cur-
rent pharmacological treatmentmodel emphasizes aggressive LDL-C lowering in middle-
aged or older adults with either established ASCVD (sec-
ondary prevention) or with a moderately increased nearer
term (10-year) risk of ASCVD events (11). However, event
rates in the drug treatment groups remain substantially
higher than in low-risk individuals, presumably because
individuals selected for treatment already have a greater
burden of advanced atherosclerosis in the setting of
continued increases in other risk factors (12).
We propose that it is now time to evaluate a radical new
approach to ASCVD prevention: “curing” atherosclerosis
itself early in the course of the disease to virtually eliminate
clinical manifestations of ASCVD later in life. In the
absence of atherosclerotic plaque, acute clinical ASCVD
events due to plaque rupture cannot occur. Of course, at
the population level, efforts to improve adherence to a
healthy lifestyle, drug therapy, and expand access to medical
care must be continued to make further progress in reducing
the burden of clinical ASCVD through primordial preven-
tion and in those in whom atherosclerosis has already
developed. However, given the difﬁculty of changing indi-
vidual human behavior and the costs associated with the
management of prevalent ASCVD, early eradication of
atherosclerosis may prove more effective than treatment later
in life when atherosclerosis is more fully established.
Moreover, such an approach could be used in the presence of
adverse risk factor levels in those who are unable or unwilling
to successfully adhere to a healthy lifestyle, with a genetic
predisposition to atherosclerosis or with high-risk conditions
such as early-onset diabetes.
Our proposed approach focuses on aggressive LDL-C
reduction. There is abundant support that LDL-C is crit-
ical in the evolution of ASCVD (13). Genetic studies show
that lifelong low LDL-C levels are associated with low
levels of atherosclerosis and coronary heart disease, even
in the presence of other ASCVD risk factors (14–16). In
one study of loss of function mutations in the proproteinconvertase subtilisin/kexin type 9 (PCSK-9) serine pro-
tease gene, middle-aged black individuals with a nonsense
mutation in PCSK-9 had 28% lower LDL-C levels than
those without such mutations, yet had an 88% reduction in
coronary heart disease (CHD) over a 15-year observation
period due to lower lifetime exposure to LDL-C (17).
Notably, this striking reduction in CHD events occurred in
the setting of a high prevalence of risk factors: body mass
index of 29.5, hypertension in 37%, diabetes in 13%, and
smoking in 27%. This low rate of CHD events occurred
with an average LDL-C level of 100 mg/dl (compared with
138 mg/dl in those without a mutation), suggesting lower
LDL-C levels may have an even greater impact on pre-
venting the development of atherosclerosis.
As atherosclerotic disease progresses with advancing
age, there is a more extensive burden of ﬁbrocalciﬁc plaque
that may be less amenable to stabilization or regression
with LDL-C–lowering treatment (18). Therefore, LDL-C
lowering may be more effective earlier in the atherosclerotic
process when more rapid and extensive plaque stabilization
and regression can occur due to reductions in lipid core
volume, inﬂammation, and early ﬁbrotic changes (19–21).
Animal and human models of atherosclerosis regression
support an early and aggressive LDL-C–lowering strategy
(22). Atherosclerosis begins with the early entry of apoli-
poprotein B–containing lipoproteins (which include LDL-C)
into the arterial wall, triggering a complex series of in-
ﬂammatory and ﬁbrotic responses leading to atheroma
formation of increasing size, stability, and likelihood of
plaque rupture (which may result in a clinical event). An-
imal models and some human observational studies suggest
that these lesions can regress with statin treatment, with
the residual lesions ranging from absent (early lesions) to
areas of ﬁbrosis devoid of active inﬂammation or lipid
(advanced lesions). Plaque regression depends on aggres-
sive lowering of LDL-C levels, generally beyond the 30%
to 50% reduction in levels of LDL-C, which would be
achieved with statin therapy (23). In several animal models,
very aggressive LDL-C reductions resulted in early loss of
foam cells from plaque and, over the longer term, resolu-
tion of necrotic regions, inﬁltration of smooth muscle cells,
especially in the ﬁbrous cap, and reductions in cholesterol
clefts and ﬁbrosis. These changes occur in both early and
more advanced lesions. Carotid endarterectomy specimens
from humans treated with statins show similar patho-
physiological changes and plaque stabilization characteristics
similar to those observed in animal studies (24), supporting
extrapolation of animal ﬁndings to human atheroma re-
sponses to LDL-C lowering.
Statins also modestly lower systolic and diastolic blood
pressure in younger individuals (25). Animal models have
shown that endothelial dysfunction from prolonged hyper-
cholesterolemia-induced atherosclerosis is a result of abnormal
nitric oxide responses, and nitric oxide responses completely
normalize with aggressive LDL-C lowering (26). Thus,
regression of atherosclerosis and subsequent normalization
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2781of arterial function with early and aggressive LDL-C
lowering could also conceivably prevent, at least in part,
the vascular changes contributing to the development of
hypertension. Human studies will be needed to determine
how much endothelial function improves with LDL-C
lowering early in the course of atherosclerosis and the
durability of the response.
Current human evidence of atherosclerosis regression.
We review current clinical evidence supporting 2 new par-
adigms of early and aggressive LDL-C–lowering therapy for
curing atherosclerosis: a very early moderate-intensity statin
LDL-C–lowering strategy in children and adolescents and
an early, very aggressive statin-based LDL-C–lowering
strategy in younger adults.
CHILDREN AND ADOLESCENTS. Familial hypercholesterole-
mia (FH) provides a genetic model for the importance of
early intervention to prevent future atherosclerosis and its
complications. Randomized trials in children with FH have
shown that atherosclerosis progression is halted by mod-
erate LDL-C reduction with pravastatin or simvastatin
over a period of 2 years (27,28). Younger children in these
trials had less atherosclerosis progression (28). No signiﬁ-
cant adverse events have been reported in pediatric statin
trials (8). Notably, in longitudinal studies of young adults
with FH, statin therapy initiated in adolescence was asso-
ciated with a reduction in ASCVD events in young
adulthood (29).
ADULTS. Statins reduce the ASCVD events in proportion to
the degree of LDL-C lowering in middle-aged and older
adults and have an extensive record of efﬁcacy and safety
(11). A 2012 meta-analysis by the Cholesterol Treatment
Trialists revealed a signiﬁcantly greater reduction in the
relative risk of major ASCVD events with statin therapy in
lower risk (<10% 5-year risk of major cardiovascular disease
[CVD]) than in higher risk individuals (10%) (Fig. 1)
(30). Age is often the strongest predictor of an ASCVDFigure 1 Effects on Major Atherosclerotic Cardiovascular Disease Ev
Individual meta-analysis of individuals free of major vascular disease at study entry enrol
RR ¼ relative risk. Adapted with permission from Cholesterol Treatment Trialists Collaboevent because it summarizes the duration of exposure to
multiple or severe levels of ASCVD risk factors (31). Thus,
given the greater relative reduction in ASCVD risk in lower
risk persons, the Cholesterol Treatment Trialists data may
imply that younger persons with less advanced atheroscle-
rosis are responding more robustly to statin therapy than
older persons with a larger burden of more advanced
atherosclerosis.
Trials of statin therapy have also shown that regression of
coronary atherosclerosis occurs in proportion to the degree
of LDL-C lowering. In the SATURN (Study of Coronary
Atheroma by Intravascular Ultrasound: Effect of Rosuvas-
tatin versus Atorvastatin), participants with a large burden of
coronary artery atherosclerosis were randomized to high-
intensity statin therapy (40 mg rosuvastatin or 80 mg ator-
vastatin, with achieved LDL-C levels of 63 mg/dl and 70
mg/dl, respectively) (32). Regression assessed by coronary
intravascular ultrasound was observed in most patients (71%
and 65%, respectively) of both treatment groups after 2 years
of treatment. In another trial of high-intensity statin therapy
in a middle-aged (mean age, 57 years) primary prevention
population with a <10% 10-year CHD risk and a lower
burden of atherosclerosis (METEOR [Measuring Effects
on Intima-Media Thickness: an Evaluation of Rosuvasta-
tin]), 40 mg rosuvastatin was compared with placebo (33).
Rosuvastatin lowered LDL-C by 49% to 78 mg/dl over a
2-year treatment period. Although regression in maximum
carotid intimal medial thickness (CIMT) was observed in
some locations (common carotid artery) in the rosuvastatin
group, the overall effect was to arrest the rate of CIMT
progression. These data suggest that even greater reductions
in LDL-C, initiated earlier in the course of atherosclerosis
and perhaps over a longer period of time than 2 years, could
induce greater atherosclerosis regression in all arterial beds.
Approach to LDL-C lowering. Some argue that pleio-
tropic, or nonlipid, effects contribute to the ASCVD event
reduction beneﬁts of statins. However, the risk reductionents per 1.0-mmol/l (39 mg/dl) Reduction in LDL-C
led in statin trials. CI ¼ conﬁdence interval; MVE ¼ major vascular event(s);
rators (30).
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LDL-C lowering and consistent with the degree of ASCVD
event reduction observed with other LDL-C–lowering ap-
proaches such as ileal bypass surgery, bile acid sequestrants,
and diet (35). These ﬁndings suggest that additional
LDL-C lowering from nonstatin agents without off-target
adverse effects may further reduce atherosclerotic progres-
sion and provide additional LDL-C event reduction to
statin therapy.
Statin therapy alone is unlikely to completely achieve the
very low LDL-C levels that appear to be needed to induce
the complete atherosclerotic regression observed in the an-
imal models reviewed earlier (22). Inhibitors of PCSK-9
inhibitors appear to be the most promising because they
enhance the activity of the LDL-C receptor to directly
remove circulating LDL-C, with an excellent margin of
safety in trials to date. Long-term outcome trials of PCSK-9
inhibitors added to maximal statin therapy are under way
and include extensive safety evaluations.
Inhibitors of PCSK-9 lower LDL-C an additional 50%
to 60% when added to statin therapy with virtually no
adverse effects found in short-term trials (36). Based on
animal and suggestive results from human studies, very
aggressively lowering LDL-C with statin/PSCK9 therapy to
levels of 30 to 40 mg/dl in adults with risk factors in the
third through ﬁfth decades of life could induce reversal of
the atherosclerotic process as well as normalize vascular
function. The duration of statin/PCSK-9 therapy needed for
these effects would need to be established, but could be as
short as 2 to 3 years.
Resetting the vascular aging clock, a new paradigm for
ASCVD prevention. Early, aggressive regression of
atherosclerosis may serve as a way to reset the vascular aging
clock in younger individuals with multiple or severe risk
factors. Because atherosclerosis is a disease that progressesFigure 2 Conceptual Model for Resetting Vascular Age Clock Appro
The relative impact of statin therapy on ASCVD events and CIMT when initiated for primar
loss of function mutation in PCSK-9 (17) are contrasted with the potential ASCVD event
sclerosis progression earlier in the life course. ASCVD ¼ atherosclerotic cardiovascular dis
C ¼ low-density lipoprotein cholesterol; PCSK-9 ¼ proprotein convertase subtilisin/kexinover decades, it may be sufﬁcient to induce regression of
existing atherosclerosis and possibly normalize arterial
function with a relatively short period of intensive treatment
to reset the vascular aging clock. Periodic re-treatment once
every decade or so would once again reset the clock (Fig. 2).
This approach is extremely attractive because lifetime drug
treatment is avoided, there is less dependence on long-term
adherence the drug therapy, costs are minimized, and the
likelihood of adverse effects is markedly reduced. Although
the long-term adverse effects of long-term therapy with
statins are unknown, they could be considerable if the excess
risk of diabetes observed in clinical trials of 2- to 5-year
duration (37,38) along with adverse muscle effects (30,39)
are projected out to 20 or 30 years. Additional advantages
include treatment of younger individuals who may have
fewer adverse effects from drug therapy than older persons
(39) and the potential to address disparities in ASCVD
incidence and prevalence in various racial, ethnic, or socio-
economic groups.
Further support for the resetting the vascular age clock
approach arises from the observation of a legacy effect of
statin therapy in long-term follow-up of several trials of
moderate-intensity statin therapy. The relative risk reduc-
tion in CVD events remained stable, and a total mortality
reduction emerged in the statin group compared with the
placebo group over the decade following trial completion,
despite substantial rates of crossovers to statin treatment in
the control groups and discontinuation of treatment in the
statin group (40,41). This observation likely reﬂects stabili-
zation and perhaps some modest regression of existing
advanced atherosclerotic plaque. This suggests that the ef-
fects of very early and/or very intensive LDL-C lowering
will persist over at least a decade. Of course, adherence to
healthy lifestyle habits is still desirable after initial treatment.
However, given the difﬁculty that many have adhering toach to the Primary Prevention of ASCVD
y prevention in middle age or older (33,34,44) and lifetime low LDL-C levels due to a
reductions from early and intensive LDL-C–lowering therapy designed to halt athero-
ease; CIMT ¼ carotid intimal medial thickness; FRS ¼ Framingham Risk Score; LDL-
type 9; RRR ¼ relative risk reduction.
Table 1
Comprehensive Research Program to Determine
Whether Resetting the Vascular Clock Approach
Will Cure Atherosclerosis
Animal models
Relate the efﬁcacy of regression treatment to the stage of atherosclerosis
pathology
Identify most the effective regression regimen and treatment threshold for
Regressing atherosclerosis
Normalizing vascular function
Establish the duration of the beneﬁt of regression treatment
Determine the optimal intervals for re-treatment to suppression of atherogenesis
Test imaging modalities with regard to atherosclerosis identiﬁcation
Subclinical atherosclerosis measures
Evaluate the performance characteristics of established subclinical measures
for estimating parameters for intervention outcomes
Regression of atherosclerosis
Normalization of vascular function
Test new modalities (e.g., magnetic resonance imaging, computed tomography
angiography) for measuring atherosclerosis regression
Compare subclinical atherosclerosis measures for predicting ASCVD outcomes
decades later
Identify optimal measure of subclinical atherosclerosis response to treatment
in terms of performance, cost, and accessibility for larger scale trials
Clinical trials: atherosclerosis regression
Determine the optimal subclinical measures for assessing treatment response
Regression of atherosclerosis
Normalization of vascular function
Determine the efﬁcacy of various intensities and durations of treatment at
various stages of atherosclerosis pathology
Identify the optimal treatment regimen to regress atherosclerosis and normalize
vascular function based on
Stage of atherosclerosis
Treatment type/intensity
LDL-C levels achieved for optimal regression/normalization
Duration of treatment
Duration of treatment effect after treatment discontinuation
Identify optimal re-treatment interval to maintain regression and normalization
of vascular function
Include safety as a critical endpoint
Evaluate the risk factors, blood biomarkers, and/or gene expression proﬁles in
response to treatment
Determine the most parsimonious and inexpensive set of measures for predicting
Regression by subclinical measures
Normalization of vascular function
Model impact of various risk stratiﬁcation strategies in various populations
for planning ASCVD outcomes trial(s)
Clinical trials: ASCVD event trials
Test hypothesis: Can atherosclerosis be cured by early and aggressive LDL-C
lowering?
Identify study population(s), intervention(s), duration of treatment and
follow-up, ASCVD primary and secondary outcomes, and sample size
Collaboration of industry and government to conduct trials
Include substudies of subclinical atherosclerosis imaging
Evaluate multicomponent predictor models to predict outcomes with
and without treatment
Quality of life studies conducted as part of the trial(s)
Cost-beneﬁt analyses conducted as part of the trial(s)
ASCVD ¼ atherosclerotic cardiovascular disease; LDL-C ¼ low-density lipoprotein cholesterol.
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2783healthy lifestyle habits and the slow progressive nature of
atherosclerosis, repeat intensive LDL-C–lowering therapy at
periodic intervals could be sufﬁcient for regressing any new
lesions that have developed during the interim. Optimal
intervals for further treatments would need to be established.
Who might be a candidate for testing a strategy that resets
the vascular aging clock? The obese young adult or older
adolescent in whom insulin resistance has already developed,
prehypertension, high triglyceride/HDL ratio, and non-
HDL cholesterol >145 to 150 mg/dl are likely to have
accelerated atherosclerosis (10,42). The PDAY (Pathologic
Determinants of Atherosclerosis in Youth) study has shown
that these individuals are likely to have as much early
atherosclerosis as children with genetic dyslipidemia (7). If
unable to respond to behavioral interventions to achieve a
healthy weight, they will have a high lifetime risk of hy-
pertension, dyslipidemia, and diabetes, ultimately leading to
premature onset of clinical CVD and death. In addition,
recent analyses of risk evolution from the TODAY (Treat-
ment Options for Type 2 Diabetes in Adolescents and
Youth) study show that adolescents with type 2 diabetes
have a rapid evolution of dyslipidemia, suggesting that
pharmacological control of these risk factors after late
metabolic complications of obesity are ﬁrmly established
may be much more difﬁcult (43). Therefore, even in the
presence of adverse risk factors, resetting the clock for
atherosclerosis early in the course of the disease would
prevent what is likely to be a major epidemic of morbidity
and mortality in an obese aging population.
Proving the paradigm. Proof-of-concept trials will need to
determine the optimal age and/or extent of atherosclerosis
for intervention, the degree of LDL-C lowering, and
duration of treatment required to induce atherosclerosis
regression and normalization of vascular function. In chil-
dren and adolescents, statin therapy would be tested. In
adults 30 to 45 years of age, very aggressive LDL-C
lowering with statin plus PCSK-9 inhibitor therapy will
need to be compared with statin therapy. Table 1 reviews a
range of research studies that could further establish the
legitimacy of the early intervention approach. Safety will need
to be carefully evaluated, and reproductive issues in women of
child-bearing potential will need to be addressed.
Measurement of CIMT by experienced research teams
currently appears to be the best noninvasive measure for
assessing atherosclerosis regression at this time. CIMT has
been successfully used to evaluate atherosclerosis progression
in children as young as 10 years of age (27,28). Based on the
magnitude of technological advances, other noninvasive
modalities for assessing response to treatment may become
available.
Although screening will include children, adolescents, and
younger adults (30 to 45 years of age) with ASCVD risk
factors, including obesity and diabetes, enrollment of only
those in the in the top quartile of CIMT for their decade of
age will increase the efﬁciency of such trials for each pop-
ulation studied. The regression trials will also need toevaluate the optimal duration of intensive treatment. A 2- to
3-year initial treatment period would be desirable, with 3
years to as long as 10 years of follow-up to determine the rate
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for retreatment.
Based on the ﬁndings from these proof-of-concept and
dose-ranging trials, long-term ASCVD outcomes trial(s)
will be the ﬁnal step. Because the hypothesis being tested is
“curing” atherosclerosis, the anticipated effect size should
be at least an 80% relative risk reduction. In a trial popu-
lation selected for an anticipated 0.2% ASCVD event rate
per year or 1% over 5 years, a sample size ofw8,000 with an
average of 5 years of treatment would have >99% power.
Ongoing developments in “virtual” trial technologies and
cell phone–based data collection will likely make such trials
relatively inexpensive to perform. These trials will also need
to include assessments of quality of life and cost. If these
trials prove that the vascular aging clock can indeed be reset,
the evidence will support future clinical recommendations
regarding early intensive LDL-C lowering to cure
atherosclerosis.
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